<p>Ventyx Biosciences, Inc.（納斯達克代碼：VTYX - 免費報告）- HC Wainwright 的研究分析師在 1 月 8 日星期四發佈的研究報告中下調了對 Ventyx Biosciences 2029 財年的每股收益（EPS）預期。HC Wainwright 分析師 E. Bodnar 現在預計該公司將在本年度發佈每股收益（$1.57），低於之前預測的（$1.50）。HC Wainwright 對該股票給予 “中性” 評級，目標價為 $14.00。市場普遍預計 Ventyx Biosciences 當前全年的每股收益為（$2.09）。</p>
<p>獲取 <strong>Ventyx Biosciences</strong> 的提醒：</p>
<p>Ventyx Biosciences（納斯達克代碼：VTYX - 獲取免費報告）最近在 11 月 6 日星期四發佈了季度財報。該公司報告季度每股收益為（$0.32），超出市場普遍預期的（$0.45）$0.13。</p>
<p>VTYX 近期成為多個報告的主題。Oppenheimer 在週四的研究報告中將 Ventyx Biosciences 的股票評級從 “跑贏大盤” 下調至 “市場表現”。Lifesci Capital 在週四的報告中重申了 “市場表現” 評級，並將 Ventyx Biosciences 的股票目標價設定為 $14.00。瑞銀集團在週四的研究報告中重申了 “中性” 評級，並將 Ventyx Biosciences 的股票目標價下調至 $14.00（之前為 $20.00）。Canaccord Genuity Group 在週四的研究報告中將 Ventyx Biosciences 的評級從 “買入” 下調至 “持有”，並將其目標價從 $16.00 降至 $14.00。最後，Clear Str 在 1 月 7 日星期三的研究報告中將 Ventyx Biosciences 的評級從 “強力買入” 下調至 “持有”。八位研究分析師對該股票給予 “持有” 評級，一位分析師對該公司的股票給予 “賣出” 評級。根據 MarketBeat.com 的數據，Ventyx Biosciences 的平均評級為 “減持”，共識目標價為 $14.86。</p>
<p><strong>閲讀我們關於 VTYX 的最新研究報告</strong></p>
<h2>Ventyx Biosciences 價格表現</h2>
<p>VTYX 股票在週一開盤價為 $13.81。該公司的市值為 $9.8548 億，市盈率為 -9.21，貝塔值為 1.23。該公司的 50 日移動平均價格為 $9.27，200 日移動平均價格為 $5.32。Ventyx Biosciences 的 12 個月低點為 $0.78，12 個月高點為 $25.00。</p>
<h2>Ventyx Biosciences 的機構交易</h2>
<p>幾家對沖基金最近調整了對 VTYX 的持股。CWM LLC 在第二季度增持了 Ventyx Biosciences 的股份，增幅為 7.6%。CWM LLC 現在擁有 57,145 股該公司的股票，價值 $122,000，此前在上個季度購買了額外的 4,057 股。Wealth Enhancement Advisory Services LLC 在第二季度增持了 Ventyx Biosciences 的股份，增幅為 21.1%。Wealth Enhancement Advisory Services LLC 現在擁有 29,657 股該公司的股票，價值 $62,000，此前在上個季度購買了額外的 5,174 股。Prelude Capital Management LLC 在第三季度增持了 Ventyx Biosciences 的股份，增幅為 35.0%。Prelude Capital Management LLC 現在擁有 21,200 股該公司的股票，價值 $66,000，此前在上個季度購買了額外的 5,500 股。Hudson Bay Capital Management LP 在第二季度購買了 Ventyx Biosciences 的新頭寸，價值約 $34,000。最後，Persistent Asset Partners Ltd 在第三季度收購了 Ventyx Biosciences 的新股份，價值約 $51,000。97.88% 的股票由機構投資者和對沖基金持有。</p>
<h2>Ventyx Biosciences 的內部交易</h2>
<p>在其他 Ventyx Biosciences 的新聞中，內部人士 John Nuss 於 12 月 18 日星期四出售了 12,675 股 Ventyx Biosciences 的股票。該股票以平均價格 $7.72 出售，總價值為 $97,851.00。出售後，內部人士持有該公司 489,481 股股票，價值約 $3,778,793.32。此次交易使其持股減少了 2.52%。該交易已在提交給證券交易委員會的文件中披露，可通過 SEC 網站訪問。此外，首席執行官 Raju Mohan 於 12 月 18 日星期四出售了 47,345 股該公司的股票。該股票以平均價格 $7.72 出售，總價值為 $365,503.40。交易後，首席執行官持有該公司 2,372,863 股股票，價值 $18,318,502.36。此次交易使其持股減少了 1.96%。有關此次出售的更多細節可在官方 SEC 披露中找到。內部人士持有該公司 18.18% 的股票。</p>
<h2>關於 Ventyx Biosciences 的熱門頭條</h2>
<p>以下是本週影響 Ventyx Biosciences 的主要新聞故事：</p>
<ul>
<li>積極情緒：Lilly 確認以每股 14.00 美元（總計約 12 億美元）收購 Ventyx 的最終協議，為股票提供了明確的現金退出和底線，而交易的風險和時間仍然存在不確定性。Lilly 將收購 Ventyx Biosciences</li>
<li>積極情緒：瑞銀開始覆蓋，給予買入評級和 20.00 美元的目標價，暗示從當前市場水平有顯著上行空間，並對 Ventyx 的資產/戰略價值向收購方傳達信心。瑞銀覆蓋報告</li>
<li>中性情緒：富國銀行重申 “持平” 評級，目標價為 14.00 美元——有效與收購價格一致，暗示在交易考慮之外短期內上行空間有限。富國銀行説明</li>
<li>中性情緒：Lifesci Capital 及其相關覆蓋在交易價格附近調整為 “市場表現”/“持有”，表明分析師將已宣佈的交易視為主要估值錨點。Lifesci/Lifesci Capital 覆蓋</li>
<li>消極情緒：多家賣方公司（Oppenheimer、Canaccord Genuity、Clear Street）在交易後下調評級或降低對 VTYX 的熱情——這些舉動可能會對剩餘流通股施加賣壓，並反映出對 14 美元報價之外上行空間的擔憂。Oppenheimer 下調 Canaccord 下調</li>
<li>消極情緒：多家律師事務所已啓動調查和股東警報，指控 Lilly 交易中可能存在不公平程序或價格不足；此類訴訟可能會延遲交易完成，增加交易成本，並增加最終股東回收的不確定性。Kahn Swick &amp; Foti 調查 Edelson Lechtzin 調查</li>
</ul>
<h2>關於 Ventyx Biosciences</h2>
<p>(獲取免費報告)</p>
<p>Ventyx Biosciences, Inc 是一家臨牀階段的生物製藥公司，開發小分子產品候選藥物以應對多種炎症性疾病。該公司的主要臨牀產品候選藥物是 VTX958，一種選擇性別構酶類型 2 抑制劑，用於治療銀屑病、銀屑病關節炎和克羅恩病。它還在開發 VTX002，一種在進行 II 期臨牀試驗的鞘氨醇 1 磷酸受體調節劑，用於治療潰瘍性結腸炎；以及 VTX2735，一種外周靶向 NOD 樣受體蛋白 3 炎症小體抑制劑，用於治療患有冷誘導週期綜合症的患者。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Ventyx Biosciences</li>
<li>巨大的機器人推廣正在進行中</li>
<li>請勿刪除，立即閲讀</li>
<li>免費：可能改變您生活的加密峯會</li>
<li>新黃金價格目標</li>
<li>但在 2026 年 5 月 20 日之前，這隻 2 美元的黃金股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlRZWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlRZWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>您現在應該投資 1,000 美元於 Ventyx Biosciences 嗎？</h2>
<p>在您考慮 Ventyx Biosciences 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Ventyx Biosciences 並不在名單上。</p>
<p>儘管 Ventyx Biosciences 目前在分析師中獲得了減持評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

VTYX

<p>HC Wainwright 已將 Ventyx Biosciences (NASDAQ:VTYX) 的 2029 財年每股收益預期從 ($1.50) 下調至 ($1.57)。該公司維持 “中性” 評級，目標價為 $14.00。市場普遍預期該公司當前財年的每股收益為 ($2.09)。最近的報告顯示，Oppenheimer 和 Canaccord Genuity 下調了評級，而 UBS Group 和 Lifesci Capital 則重申了他們的目標價。VTYX 股票開盤價為 $13.81，市值為 9.8548 億美元，12 個月高點為 $25.00</p>

<p>Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) - Research analysts at HC Wainwright cut their FY2029 earnings per share (EPS) estimates for Ventyx Biosciences in a research note issued on Thursday, January 8th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($1.57) per share for the year, down from their previous forecast of ($1.50). HC Wainwright has a &#34;Neutral&#34; rating and a $14.00 price objective on the stock. The consensus estimate for Ventyx Biosciences' current full-year earnings is ($2.09) per share.</p>
<div class="lb-trans"><p>Ventyx Biosciences, Inc.（納斯達克代碼：VTYX - 免費報告）- HC Wainwright 的研究分析師在 1 月 8 日星期四發佈的研究報告中下調了對 Ventyx Biosciences 2029 財年的每股收益（EPS）預期。HC Wainwright 分析師 E. Bodnar 現在預計該公司將在本年度發佈每股收益（$1.57），低於之前預測的（$1.50）。HC Wainwright 對該股票給予 “中性” 評級，目標價為 $14.00。市場普遍預計 Ventyx Biosciences 當前全年的每股收益為（$2.09）。</p>
</div><p>Get <strong>Ventyx Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Ventyx Biosciences</strong> 的提醒：</p>
</div><p>Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.13.</p>
<div class="lb-trans"><p>Ventyx Biosciences（納斯達克代碼：VTYX - 獲取免費報告）最近在 11 月 6 日星期四發佈了季度財報。該公司報告季度每股收益為（$0.32），超出市場普遍預期的（$0.45）$0.13。</p>
</div><p>VTYX has been the topic of several other reports. Oppenheimer downgraded shares of Ventyx Biosciences from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Thursday. Lifesci Capital reissued a &#34;market perform&#34; rating and set a $14.00 price target on shares of Ventyx Biosciences in a report on Thursday. UBS Group restated a &#34;neutral&#34; rating and issued a $14.00 price target (down previously from $20.00) on shares of Ventyx Biosciences in a research report on Thursday. Canaccord Genuity Group downgraded Ventyx Biosciences from a &#34;buy&#34; rating to a &#34;hold&#34; rating and reduced their price objective for the company from $16.00 to $14.00 in a research note on Thursday. Finally, Clear Str cut Ventyx Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, January 7th. Eight research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Ventyx Biosciences has an average rating of &#34;Reduce&#34; and a consensus target price of $14.86.</p>
<div class="lb-trans"><p>VTYX 近期成為多個報告的主題。Oppenheimer 在週四的研究報告中將 Ventyx Biosciences 的股票評級從 “跑贏大盤” 下調至 “市場表現”。Lifesci Capital 在週四的報告中重申了 “市場表現” 評級，並將 Ventyx Biosciences 的股票目標價設定為 $14.00。瑞銀集團在週四的研究報告中重申了 “中性” 評級，並將 Ventyx Biosciences 的股票目標價下調至 $14.00（之前為 $20.00）。Canaccord Genuity Group 在週四的研究報告中將 Ventyx Biosciences 的評級從 “買入” 下調至 “持有”，並將其目標價從 $16.00 降至 $14.00。最後，Clear Str 在 1 月 7 日星期三的研究報告中將 Ventyx Biosciences 的評級從 “強力買入” 下調至 “持有”。八位研究分析師對該股票給予 “持有” 評級，一位分析師對該公司的股票給予 “賣出” 評級。根據 MarketBeat.com 的數據，Ventyx Biosciences 的平均評級為 “減持”，共識目標價為 $14.86。</p>
</div><p><strong>Read Our Latest Research Report on VTYX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 VTYX 的最新研究報告</strong></p>
</div><h2>Ventyx Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Ventyx Biosciences 價格表現</h2>
</div><p>VTYX stock opened at $13.81 on Monday. The company has a market cap of $985.48 million, a price-to-earnings ratio of -9.21 and a beta of 1.23. The company has a fifty day moving average price of $9.27 and a 200 day moving average price of $5.32. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $25.00.</p>
<div class="lb-trans"><p>VTYX 股票在週一開盤價為 $13.81。該公司的市值為 $9.8548 億，市盈率為 -9.21，貝塔值為 1.23。該公司的 50 日移動平均價格為 $9.27，200 日移動平均價格為 $5.32。Ventyx Biosciences 的 12 個月低點為 $0.78，12 個月高點為 $25.00。</p>
</div><h2>Institutional Trading of Ventyx Biosciences</h2>
<div class="lb-trans"><h2>Ventyx Biosciences 的機構交易</h2>
</div><p>Several hedge funds have recently modified their holdings of VTYX. CWM LLC boosted its stake in shares of Ventyx Biosciences by 7.6% during the 2nd quarter. CWM LLC now owns 57,145 shares of the company's stock worth $122,000 after purchasing an additional 4,057 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Ventyx Biosciences by 21.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company's stock valued at $62,000 after buying an additional 5,174 shares during the last quarter. Prelude Capital Management LLC raised its position in shares of Ventyx Biosciences by 35.0% in the third quarter. Prelude Capital Management LLC now owns 21,200 shares of the company's stock valued at $66,000 after buying an additional 5,500 shares during the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of Ventyx Biosciences during the second quarter valued at approximately $34,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Ventyx Biosciences during the third quarter worth approximately $51,000. 97.88% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家對沖基金最近調整了對 VTYX 的持股。CWM LLC 在第二季度增持了 Ventyx Biosciences 的股份，增幅為 7.6%。CWM LLC 現在擁有 57,145 股該公司的股票，價值 $122,000，此前在上個季度購買了額外的 4,057 股。Wealth Enhancement Advisory Services LLC 在第二季度增持了 Ventyx Biosciences 的股份，增幅為 21.1%。Wealth Enhancement Advisory Services LLC 現在擁有 29,657 股該公司的股票，價值 $62,000，此前在上個季度購買了額外的 5,174 股。Prelude Capital Management LLC 在第三季度增持了 Ventyx Biosciences 的股份，增幅為 35.0%。Prelude Capital Management LLC 現在擁有 21,200 股該公司的股票，價值 $66,000，此前在上個季度購買了額外的 5,500 股。Hudson Bay Capital Management LP 在第二季度購買了 Ventyx Biosciences 的新頭寸，價值約 $34,000。最後，Persistent Asset Partners Ltd 在第三季度收購了 Ventyx Biosciences 的新股份，價值約 $51,000。97.88% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Insider Transactions at Ventyx Biosciences</h2>
<div class="lb-trans"><h2>Ventyx Biosciences 的內部交易</h2>
</div><p>In other Ventyx Biosciences news, insider John Nuss sold 12,675 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the sale, the insider owned 489,481 shares of the company's stock, valued at approximately $3,778,793.32. The trade was a 2.52% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the business's stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the transaction, the chief executive officer owned 2,372,863 shares in the company, valued at $18,318,502.36. The trade was a 1.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 18.18% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Ventyx Biosciences 的新聞中，內部人士 John Nuss 於 12 月 18 日星期四出售了 12,675 股 Ventyx Biosciences 的股票。該股票以平均價格 $7.72 出售，總價值為 $97,851.00。出售後，內部人士持有該公司 489,481 股股票，價值約 $3,778,793.32。此次交易使其持股減少了 2.52%。該交易已在提交給證券交易委員會的文件中披露，可通過 SEC 網站訪問。此外，首席執行官 Raju Mohan 於 12 月 18 日星期四出售了 47,345 股該公司的股票。該股票以平均價格 $7.72 出售，總價值為 $365,503.40。交易後，首席執行官持有該公司 2,372,863 股股票，價值 $18,318,502.36。此次交易使其持股減少了 1.96%。有關此次出售的更多細節可在官方 SEC 披露中找到。內部人士持有該公司 18.18% 的股票。</p>
</div><h2>Trending Headlines about Ventyx Biosciences</h2>
<div class="lb-trans"><h2>關於 Ventyx Biosciences 的熱門頭條</h2>
</div><p>Here are the key news stories impacting Ventyx Biosciences this week:</p>
<div class="lb-trans"><p>以下是本週影響 Ventyx Biosciences 的主要新聞故事：</p>
</div><ul>
<li>Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences</li>
<li>Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported</li>
<li>Neutral Sentiment: Wells Fargo reaffirmed an &#34;equal weight&#34; rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note</li>
<li>Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to &#34;market perform&#34;/&#34;hold&#34; around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage</li>
<li>Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgradeCanaccord downgrade</li>
<li>Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick &amp; Foti investigationEdelson Lechtzin investigation</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：Lilly 確認以每股 14.00 美元（總計約 12 億美元）收購 Ventyx 的最終協議，為股票提供了明確的現金退出和底線，而交易的風險和時間仍然存在不確定性。Lilly 將收購 Ventyx Biosciences</li>
<li>積極情緒：瑞銀開始覆蓋，給予買入評級和 20.00 美元的目標價，暗示從當前市場水平有顯著上行空間，並對 Ventyx 的資產/戰略價值向收購方傳達信心。瑞銀覆蓋報告</li>
<li>中性情緒：富國銀行重申 “持平” 評級，目標價為 14.00 美元——有效與收購價格一致，暗示在交易考慮之外短期內上行空間有限。富國銀行説明</li>
<li>中性情緒：Lifesci Capital 及其相關覆蓋在交易價格附近調整為 “市場表現”/“持有”，表明分析師將已宣佈的交易視為主要估值錨點。Lifesci/Lifesci Capital 覆蓋</li>
<li>消極情緒：多家賣方公司（Oppenheimer、Canaccord Genuity、Clear Street）在交易後下調評級或降低對 VTYX 的熱情——這些舉動可能會對剩餘流通股施加賣壓，並反映出對 14 美元報價之外上行空間的擔憂。Oppenheimer 下調 Canaccord 下調</li>
<li>消極情緒：多家律師事務所已啓動調查和股東警報，指控 Lilly 交易中可能存在不公平程序或價格不足；此類訴訟可能會延遲交易完成，增加交易成本，並增加最終股東回收的不確定性。Kahn Swick &amp; Foti 調查 Edelson Lechtzin 調查</li>
</ul>
</div><h2>About Ventyx Biosciences</h2>
<div class="lb-trans"><h2>關於 Ventyx Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.</p>
<div class="lb-trans"><p>Ventyx Biosciences, Inc 是一家臨牀階段的生物製藥公司，開發小分子產品候選藥物以應對多種炎症性疾病。該公司的主要臨牀產品候選藥物是 VTX958，一種選擇性別構酶類型 2 抑制劑，用於治療銀屑病、銀屑病關節炎和克羅恩病。它還在開發 VTX002，一種在進行 II 期臨牀試驗的鞘氨醇 1 磷酸受體調節劑，用於治療潰瘍性結腸炎；以及 VTX2735，一種外周靶向 NOD 樣受體蛋白 3 炎症小體抑制劑，用於治療患有冷誘導週期綜合症的患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Ventyx Biosciences</li>
<li>Huge robotics rollout underway</li>
<li>Do not delete, read immediately</li>
<li>Free: The Crypto Summit That Could Change Your Life</li>
<li>New gold price target</li>
<li>But this $2 Gold Stock Before May 20, 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Ventyx Biosciences</li>
<li>巨大的機器人推廣正在進行中</li>
<li>請勿刪除，立即閲讀</li>
<li>免費：可能改變您生活的加密峯會</li>
<li>新黃金價格目標</li>
<li>但在 2026 年 5 月 20 日之前，這隻 2 美元的黃金股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlRZWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=VTYX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ventyx Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元於 Ventyx Biosciences 嗎？</h2>
</div><p>Before you consider Ventyx Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Ventyx Biosciences 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Ventyx Biosciences 並不在名單上。</p>
</div><p>While Ventyx Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Ventyx Biosciences 目前在分析師中獲得了減持評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 對 Ventyx Biosciences 2029 財年的收益預估為負